Mekinist for gliomas – pro
The strategy of testing for markers and tailoring treatment to them, irrespective of the medical ,literature or whether there is suffiicnet published evidence for a treatment, is currently considered experimental. The published evidence is at the level of case reports and cannot be known to be more beenficial than standard therapies, whcic in this case, after multiple failed therapies, would be palliative care. The only study that I found was for dabrafenib and ti was Phase I/II. It suggests that dabrafenib shrinks or stabilizes low-grade gliomas in children with the BRAF V600E mutation. Objective, durable responses occurred in 38% of patients, and the side effects were less severe than with chemotherapy. I was not able to find studies published abouut the use of Mekinist (trametinib).
Giles W Robinson, E Brent A Orr and Amar Gajjar, Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer201414:258
Dabrafenib Effective in Pediatric Glioma DOI: 10.1158/2159-8290.CD-NB2016-140 Published November 2016
Catherine Louise Penman et al,Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas. Front Oncol. 2015; 5: 54.